# Furosemide in severe bronchopulmonary dysplasia: comparative effectiveness of a duration and dosage informed treatment strategy

> **NIH NIH K23** · CHILDREN'S HOSP OF PHILADELPHIA · 2020 · $158,328

## Abstract

PROJECT SUMMARY/ABSTRACT
 The purpose of this Mentored Patient-Oriented Research Career Development Award (K23) is to
provide Nicolas A. Bamat, MD, MSCE, Instructor of Pediatrics at the Perelman School of Medicine at the
University of Pennsylvania (Penn) and The Children’s Hospital of Philadelphia (CHOP) with the mentorship,
training and research experience needed to become an independent clinical investigator. His long-term career
goal is to improve outcomes for infants with neonatal lung disease by leading trials that identify evidence-
based pharmacotherapeutic practices. His immediate career development goal is to acquire the skills needed
to ensure a successful transition to research independence. To meet this goal, Dr. Bamat and his mentor team
have devised a career development plan that integrates: (1) intensive mentorship from successful pediatric
investigators; (2) focused training in clinical trials, clinical pharmacology and longitudinal data analysis; and (3)
innovative research on furosemide treatment strategies for severe bronchopulmonary dysplasia (BPD).
 Complications of preterm birth are the leading pediatric contributor to disability-adjusted life years lost.
BPD, or chronic lung disease of prematurity, is the most common major morbidity. BPD is particularly
devastating for infants with severe BPD (sBPD), the worst severity class. Prolonged initial hospitalizations, co-
morbid pulmonary hypertension, tracheostomy for prolonged ventilation and childhood death are common.
Currently, no pharmacotherapies have proven clinical efficacy for improving respiratory disease course in
sBPD. Despite this, medication exposures are common. The loop diuretic furosemide is most frequently used.
Dr. Bamat’s mentored research will address key knowledge gaps surrounding furosemide use in sBPD. He will:
(1) determine if and when tolerance to furosemide diuresis occurs in sBPD, (2) develop furosemide population
pharmacokinetic models with covariate analysis for individualized dosage regimens, and (3) apply the
knowledge gained in (1) and (2) to determine the comparative effectiveness of an informed furosemide
treatment strategy versus standard of care for improving the respiratory severity score and decreasing the rate
of furosemide-associated adverse effects. This research will be conducted by leveraging the existence of
CHOP’s Chronic Lung Disease Program, a multidisciplinary referral program dedicated to infants with sBPD.
 Dr. Bamat’s findings will guide furosemide treatment strategies in sBPD, for testing in placebo-
controlled multicenter trials, funded through R-series awards in his transition to research independence. The
described career development and research activities will occur at Penn and CHOP, an ideal environment in
which to train the next generation of scientists conducting NIH-supported patient-oriented research.

## Key facts

- **NIH application ID:** 9953155
- **Project number:** 1K23HD101651-01
- **Recipient organization:** CHILDREN'S HOSP OF PHILADELPHIA
- **Principal Investigator:** Nicolas Augusto Bamat
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $158,328
- **Award type:** 1
- **Project period:** 2020-09-04 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9953155

## Citation

> US National Institutes of Health, RePORTER application 9953155, Furosemide in severe bronchopulmonary dysplasia: comparative effectiveness of a duration and dosage informed treatment strategy (1K23HD101651-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9953155. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*